Tesofensine
Tesofensine is a triple monoamine (serotonin-norepinephrine-dopamine) reuptake inhibitor originally developed for Alzheimer's and Parkinson's disease that showed larger-than-typical weight loss in phase 2 obesity trials, but it has never been approved for any indication and its obesity development program has seen repeated delays.
This page is a research-orientation summary, not a dosing guide. For anything beyond general background, read the primary literature or talk to a qualified clinician — specifics like amount, frequency, or administration aren't something we publish here.
What it does & how it works
Tesofensine blocks presynaptic reuptake transporters for serotonin, norepinephrine, and dopamine, increasing the synaptic availability of all three neurotransmitters in the central nervous system. In hypothalamic appetite-regulating circuits, animal studies indicate this occurs largely through indirect stimulation of alpha-1 adrenergic and dopamine D1 receptor pathways, thought to drive its pronounced appetite-suppressing effect. This central, neurotransmitter-based mechanism is distinct from the gut-hormone (GLP-1/GIP receptor) mechanism used by newer injectable obesity drugs.
Typical results seen in research
In a 24-week randomized, double-blind, placebo-controlled phase 2 trial in obese adults, tesofensine produced dose-dependent weight loss substantially greater than placebo, generating interest as a potentially more potent oral option than older appetite suppressants. Human evidence, however, is limited to phase 2-scale, medium-duration trials; no completed phase 3 program or large, long-term safety dataset has been published, and increases in heart rate observed in trials warrant caution given the cardiovascular safety history of older serotonergic/monoamine diet drugs.
How it’s commonly used
In the clinical trials conducted to date, tesofensine has been administered orally as a once-daily capsule or tablet. It is not currently approved by the FDA, EMA, or any other regulatory agency for any indication, and remains an investigational compound used only in research settings rather than an established clinical weight-loss protocol.
- The Lancet · 2008 Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial
- Neuropsychopharmacology · 2010 Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat
Curated from published literature for research orientation. Not an exhaustive review, and not a substitute for reading primary sources.